Publication: CRISPR-on-chip for point-of-care diagnostics
| dc.contributor.department | KUTTAM (Koç University Research Center for Translational Medicine) | |
| dc.contributor.department | KUIS AI (Koç University & İş Bank Artificial Intelligence Center) | |
| dc.contributor.department | Department of Mechanical Engineering | |
| dc.contributor.department | School of Medicine | |
| dc.contributor.department | KUAR (KU Arçelik Research Center for Creative Industries) | |
| dc.contributor.department | Graduate School of Sciences and Engineering | |
| dc.contributor.kuauthor | Atçeken, Nazente | |
| dc.contributor.kuauthor | Yığcı, Defne | |
| dc.contributor.kuauthor | Taşoğlu, Savaş | |
| dc.contributor.kuauthor | Kahya, Alptekin | |
| dc.contributor.schoolcollegeinstitute | Research Center | |
| dc.contributor.schoolcollegeinstitute | College of Engineering | |
| dc.contributor.schoolcollegeinstitute | SCHOOL OF MEDICINE | |
| dc.contributor.schoolcollegeinstitute | GRADUATE SCHOOL OF SCIENCES AND ENGINEERING | |
| dc.date.accessioned | 2026-02-26T07:11:26Z | |
| dc.date.available | 2026-02-25 | |
| dc.date.issued | 2026 | |
| dc.description.abstract | CRISPR-based diagnostic platforms have gained significant momentum in recent years, enabling highly sensitive and specific detection of pathogens and diseases. Due to their practical benefits, these platforms have become widely adopted in point-of-care (PoC) applications. CRISPR-on-chip technology integrates CRISPR-Cas platforms with diverse microfluidic systems, allowing scalability and portable, real-time, and precise biomolecule detection. This approach enhances diagnostic accuracy, reduces processing times, and minimizes the need for complex laboratory infrastructures, unlike in conventional diagnostics. Using CRISPR-Cas enzymes in microfluidic systems, CRISPR-on-chip platforms offer key advantages such as single-molecule sensitivity, multiplex detection, and applicability. However, integration with microfluidics for PoC applications is still poorly understood, despite CRISPR-Cas being widely used. This study reviews recent developments in CRISPR-on-chip-based diagnostics and highlights its potential applications in infectious diseases, biosensors, and personalized medicine. Furthermore, challenges and future perspectives in achieving an ideal diagnostic solution are discussed. | |
| dc.description.fulltext | Yes | |
| dc.description.harvestedfrom | Manual | |
| dc.description.indexedby | WOS | |
| dc.description.indexedby | Scopus | |
| dc.description.indexedby | PubMed | |
| dc.description.openaccess | Gold OA | |
| dc.description.openaccess | Green OA | |
| dc.description.peerreviewstatus | N/A | |
| dc.description.publisherscope | International | |
| dc.description.readpublish | N/A | |
| dc.description.sponsoredbyTubitakEu | TÜBİTAK | |
| dc.description.sponsorship | S.T. acknowledges TUBITAK 2232 International Fellowship for Outstanding Researchers Award (118C391), TUBITAK-1001 Scientific and Technological Research Projects (123S582, 123Z050, 225S122, 125Z215), Alexander von Humboldt Research Fellowship for Experienced Researchers, Marie Sk & lstrok;odowska-Curie Individual Fellowship (101003361), and Royal Academy Newton-Katip Celebi Transforming Systems Through Partnership Award (120N019) for the financial support of this research. N.A. acknowledges support by EMBO Scientific Exchange Grant (11627) and TUBITAK-2218 Domestic Postdoctoral Research Scholarship Project (122C195). Opinions, interpretations, conclusions, and recommendations are those of the author and are not necessarily endorsed by the TUBITAK. This work was partially supported by the Science Academy's Young Scientist Awards Program (BAGEP), Outstanding Young Scientists Awards (GEBIP), Dr. Nejat Eczacibasi Medicine Incentive Award, IBG Science Medal from Izmir Biomedicine and Genome Center, ELGINKAN Foundation Technology Prize, TGC Sedat Simavi Health Sciences Award, Parlar Foundation Research Incentive Award, Parlar Foundation Technology Incentive Award, and Bilim Kahramanlari Dernegi The Young Scientist Award. This study was conducted using the service and infrastructure of Koc University Translational Medicine Research Center (KUTTAM). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Illustrations from the Figures were used from BioRender.com. | |
| dc.description.version | N/A | |
| dc.identifier.doi | 10.1021/acsnano.5c19771 | |
| dc.identifier.eissn | 1936-086X | |
| dc.identifier.embargo | No | |
| dc.identifier.endpage | 2577 | |
| dc.identifier.grantno | 118C391 | |
| dc.identifier.grantno | 101003361 | |
| dc.identifier.issn | 1936-0851 | |
| dc.identifier.issue | 3 | |
| dc.identifier.pubmed | 41527500 | |
| dc.identifier.quartile | Q1 | |
| dc.identifier.scopus | 2-s2.0-105028700128 | |
| dc.identifier.startpage | 2561 | |
| dc.identifier.uri | https://doi.org/10.1021/acsnano.5c19771 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14288/32401 | |
| dc.identifier.volume | 20 | |
| dc.identifier.wos | 001661052200001 | |
| dc.keywords | CRISPR-based diagnostic | |
| dc.keywords | Microfluidics | |
| dc.keywords | Point-of-care (PoC) | |
| dc.keywords | CRISPR-on-chip technology | |
| dc.language.iso | eng | |
| dc.publisher | American Chemical Society | |
| dc.relation.affiliation | Koç University | |
| dc.relation.collection | Koç University Institutional Repository | |
| dc.relation.ispartof | ACS Nano | |
| dc.relation.openaccess | Yes | |
| dc.rights | CC BY-NC-ND (Attribution-NonCommercial-NoDerivs) | |
| dc.rights.uri | Attribution, Non-commercial, No Derivative Works (CC-BY-NC-ND) | |
| dc.subject | Chemistry | |
| dc.subject | Science and technology | |
| dc.subject | Materials science | |
| dc.title | CRISPR-on-chip for point-of-care diagnostics | |
| dc.type | Review | |
| dspace.entity.type | Publication | |
| relation.isOrgUnitOfPublication | 91bbe15d-017f-446b-b102-ce755523d939 | |
| relation.isOrgUnitOfPublication | 77d67233-829b-4c3a-a28f-bd97ab5c12c7 | |
| relation.isOrgUnitOfPublication | ba2836f3-206d-4724-918c-f598f0086a36 | |
| relation.isOrgUnitOfPublication | d02929e1-2a70-44f0-ae17-7819f587bedd | |
| relation.isOrgUnitOfPublication | 738de008-9021-4b5c-a60b-378fded7ef70 | |
| relation.isOrgUnitOfPublication | 3fc31c89-e803-4eb1-af6b-6258bc42c3d8 | |
| relation.isOrgUnitOfPublication.latestForDiscovery | 91bbe15d-017f-446b-b102-ce755523d939 | |
| relation.isParentOrgUnitOfPublication | d437580f-9309-4ecb-864a-4af58309d287 | |
| relation.isParentOrgUnitOfPublication | 8e756b23-2d4a-4ce8-b1b3-62c794a8c164 | |
| relation.isParentOrgUnitOfPublication | 17f2dc8e-6e54-4fa8-b5e0-d6415123a93e | |
| relation.isParentOrgUnitOfPublication | 434c9663-2b11-4e66-9399-c863e2ebae43 | |
| relation.isParentOrgUnitOfPublication.latestForDiscovery | d437580f-9309-4ecb-864a-4af58309d287 |
